Showing items 1 - 3 of 3

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

- Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil

Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows

- Regan, Megan, Fleming, Gini, Walley, Barbara, Francis, Prudence, Pagani, Olivia

Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy

- Bellet, Meritxell, Gray, Kathryn, Gonzales-Martin, Antonio, Ferrer, Roser, Catalan, Roberto, Azaro, Analia, Rajasekaran, Agnita, Morales, Josefa, Vazquez, Josep, Fleming, Gini, Price, Karen, Regan, Meredith, Francis, Prudence, Lang, Istvan, Ciruelos, Eva, Lluch, Ana, Climent, Miguel Angel, Catalan, Gustavo, Avella, Antoni, Bohn, Uriel

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit